TyRx Pharma Inc. Announces FDA 510(k) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacemaker or Implantable Cardioverter
Published: Jan 17, 2008
MONMOUTH JUNCTION, NJ--(Marketwire - January 17, 2008) - TyRx Pharma, Inc., a leader in the commercialization of implantable combination drug-device products, announced today the Food and Drug Administration (FDA) clearance of a Premarket 510(k) Application to market its AIGIS(Rx)™ CRMD Anti-Bacterial Envelope. CRMD post-implant infection including cases of "super bug" or MRSA is a growing and potentially fatal complication.